Patents by Inventor Kunwar Shailubhai

Kunwar Shailubhai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
    Publication number: 20200009063
    Abstract: The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: June 26, 2018
    Publication date: January 9, 2020
    Inventors: Kunwar SHAILUBHAI, Stephen COMISKEY
  • FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
    Publication number: 20190321439
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: March 18, 2019
    Publication date: October 24, 2019
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Process of preparing guanylate cyclase C agonisys
    Patent number: 10421787
    Abstract: The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: September 24, 2019
    Assignee: Bausch Health Ireland Limited
    Inventors: Juncai Bai, Ruoping Zhang, Jun Jian, Junfeng Zhou, Qiao Zhao, Guoquing Zhang, Kunwar Shailubhai, Stephen Comiskey, Rong Feng
  • COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
    Publication number: 20190262420
    Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.
    Type: Application
    Filed: February 14, 2019
    Publication date: August 29, 2019
    Inventor: Kunwar SHAILUBHAI
  • AGONISTS OF GUANYLATE CYCLASE AND THEIR USES
    Publication number: 20190263861
    Abstract: This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents.
    Type: Application
    Filed: October 3, 2018
    Publication date: August 29, 2019
    Inventor: Kunwar SHAILUBHAI
  • Agonists of guanylate cyclase and their uses
    Patent number: 10342848
    Abstract: This invention provides a method of colonic cleansing.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: July 9, 2019
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Dennis Riff, Gary S. Jacob, Kunwar Shailubhai, Patrick H. Griffin
  • FORMULATIONS OF MILCICLIB AND THERAPEUTIC COMBINATIONS OF THE SAME FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20190134044
    Abstract: This application relates to methods of treating and/or preventing cancer (e.g., non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma) in patients in need thereof comprising administering to the patient a therapeutically effective amount of a CDK inhibitor (e.g., milciclib) in combination with a therapeutically effective amount of another anticancer drug (e.g., sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib).
    Type: Application
    Filed: November 6, 2018
    Publication date: May 9, 2019
    Inventor: Kunwar SHAILUBHAI
  • Compositions useful for the treatment of gastrointestinal disorders
    Patent number: 10238712
    Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: March 26, 2019
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventor: Kunwar Shailubhai
  • Formulations of guanylate cyclase C agonists and methods of use
    Patent number: 10232011
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: March 19, 2019
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • FORMULATIONS AND METHODS FOR TREATING ULCERATIVE COLITIS
    Publication number: 20190030116
    Abstract: This invention provides composition and methods to prevent, treat or alleviate a symptom of ulcerative colitis comprising administering to a patient dolcanatide.
    Type: Application
    Filed: January 11, 2017
    Publication date: January 31, 2019
    Inventors: Kunwar SHAILUBHAI, Gary S. JACOB, Patrick GRIFFIN
  • ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME
    Publication number: 20190002501
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Application
    Filed: June 5, 2018
    Publication date: January 3, 2019
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Agonists of guanylate cyclase and their uses
    Patent number: 10118946
    Abstract: This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: November 6, 2018
    Assignee: SYNERGY PHARMACEUTICALS INC.
    Inventor: Kunwar Shailubhai
  • USE OF A COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH CDK2 INHIBITORS IN THE TREATMENT OF CANCER
    Publication number: 20180311245
    Abstract: The present disclosure relates to methods of treating cancer and pharmaceutical compositions for use in the treatment of cancer, including LSD1-inhibitor-resistant cancers, comprising administering to a subject an effective amount of a CDK2 inhibitor and an effective amount of a LSD1 inhibitor.
    Type: Application
    Filed: April 25, 2018
    Publication date: November 1, 2018
    Inventor: Kunwar SHAILUBHAI
  • AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS
    Publication number: 20180273586
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
    Type: Application
    Filed: March 12, 2018
    Publication date: September 27, 2018
    Inventors: Kunwar SHAILUBHAI, Gary S. JACOB
  • Formulations of guanylate cyclase C agonists and methods of use
    Patent number: 10034836
    Abstract: The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: July 31, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Stephen Comiskey
  • FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
    Publication number: 20180207229
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: March 19, 2018
    Publication date: July 26, 2018
    Inventors: Stephen COMISKEY, Rong FENG, John FOSS, Kunwar SHAILUBHAI
  • Ultra-pure agonists of guanylate cyclase C, method of making and using same
    Patent number: 10011637
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 3, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • DACTINOMYCIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA
    Publication number: 20180092857
    Abstract: The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.
    Type: Application
    Filed: September 13, 2017
    Publication date: April 5, 2018
    Inventor: Kunwar SHAILUBHAI
  • Formulations of guanylate cyclase C agonists and methods of use
    Patent number: 9925231
    Abstract: The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: March 27, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Stephen Comiskey, Rong Feng, John Foss, Kunwar Shailubhai
  • Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    Patent number: 9920095
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorder, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: March 20, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Gary S. Jacob